Diana Barb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Diana Barb has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth Cusi
Division of Endocrinology, Diabetes and Metabolism The University of Florida Gainesville Florida USA
4 shared publications - Fernando Bril
Division of Endocrinology, Diabetes and Metabolism University of Alabama at Birmingham Birmingham Alabama USA
3 shared publications - Anu Sharma
College of Medicine, University of Florida, Gainesville, USA
2 shared publications - Layla A. Abushamat
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
2 shared publications - Nada Fanous
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States
2 shared publications Pir Ahmad Shah
Gastroenterology and Hepatology, Creighton University, Phoenix, Arizona USA
2 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , e1813-e1822
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.
- 11 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , e1813-e1822
Open AccessSeverity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.
- 26 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1039-1045
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
- 26 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1039-1045
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
- Open Access
- 30 July 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (6) , 458-464
Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease
- 30 July 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (6) , 458-464
Open AccessPlain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease
- 25 April 2025
- Published by Springer Nature
- p. 199-215
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
- 25 April 2025
- Published by Springer Nature
- p. 199-215
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
- Top Cited PapersOpen Access
- 15 February 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 22 (8) , 1565-1574
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
- 15 February 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 22 (8) , 1565-1574
Top Cited PapersOpen AccessThe Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
- Top Cited Papers
- 17 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (5) , 1797-1835
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
- 17 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (5) , 1797-1835
Top Cited PapersAASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
- Open Access
- 5 July 2021
- Published by Wiley in Liver International
- Vol. 41 (11) , 2659-2670
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
Background and Aims: Peroxisome proliferator‐activated receptor (PPAR)‐γ agonists decrease hepatic/visceral fat (VF) and improve necroinflammation despite subcutaneous (SC) fat weight‐gain. Understanding the impact of changes in VF, VF‐to‐SC fat distribution (VF/SC) and adiponectin (ADPN) levels in relation to histological improvement after weight‐loss or pioglitazone is relevant as novel PPAR‐γ agonists are being developed for treating non‐alcoholic steatohepatitis (NASH).Methods: Fifty‐five patients with NASH received a −500 kcal/d hypocaloric diet and were randomized (double‐blind) to pioglitazone (45 mg/d) or placebo for 6‐months. Before and after treatment patients underwent a liver biopsy and measurement of hepatic/peripheral glucose fluxes, hepatic/adipose tissue‐IR and, in 35 patients, hepatic and VF/SC‐fat was measured by magnetic resonance spectroscopy/imaging. Data were examined by multivariable statistical analyses combined with machine‐learning techniques (partial least square discriminant analysis [PLS‐DA]).Results: Both pioglitazone (despite weight‐gain) and placebo (if weight‐loss) reduced steatosis but only pioglitazone ameliorated necroinflammation. Using machine‐learning PLS‐DA showed that the treatment differences induced by a PPAR‐γ agonist vs placebo on metabolic variables and liver histology could be best explained by the increase in ADPN and a decrease in VF/SC, and to a lesser degree, improvement in oral glucose tolerance test‐glucose concentrations and ALT. Decrease in steatosis and disease activity score (ballooning plus lobular inflammation) kept a close relationship with an increase in ADPN (r = −.71 and r = −.44, P < .007, respectively) and reduction in VF/SC fat (r = .41 and r = .37, P < .03 respectively).Conclusions: Reduction in VF and improved VF/SC‐distribution, combined with an increase in ADPN, mediate the histological benefits of PPAR‐γ action, highlighting the central role of fat metabolism and its distribution on steatohepatitis disease activity in patients with NASH.
- 5 July 2021
- Published by Wiley in Liver International
- Vol. 41 (11) , 2659-2670
Open AccessPPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
Background and Aims: Peroxisome proliferator‐activated receptor (PPAR)‐γ agonists decrease hepatic/visceral fat (VF) and improve necroinflammation despite subcutaneous (SC) fat weight‐gain. Understanding the impact of changes in VF, VF‐to‐SC fat distribution (VF/SC) and adiponectin (ADPN) levels in relation to histological improvement after weight‐loss or pioglitazone is relevant as novel PPAR‐γ agonists are being developed for treating non‐alcoholic steatohepatitis (NASH).Methods: Fifty‐five patients with NASH received a −500 kcal/d hypocaloric diet and were randomized (double‐blind) to pioglitazone (45 mg/d) or placebo for 6‐months. Before and after treatment patients underwent a liver biopsy and measurement of hepatic/peripheral glucose fluxes, hepatic/adipose tissue‐IR and, in 35 patients, hepatic and VF/SC‐fat was measured by magnetic resonance spectroscopy/imaging. Data were examined by multivariable statistical analyses combined with machine‐learning techniques (partial least square discriminant analysis [PLS‐DA]).Results: Both pioglitazone (despite weight‐gain) and placebo (if weight‐loss) reduced steatosis but only pioglitazone ameliorated necroinflammation. Using machine‐learning PLS‐DA showed that the treatment differences induced by a PPAR‐γ agonist vs placebo on metabolic variables and liver histology could be best explained by the increase in ADPN and a decrease in VF/SC, and to a lesser degree, improvement in oral glucose tolerance test‐glucose concentrations and ALT. Decrease in steatosis and disease activity score (ballooning plus lobular inflammation) kept a close relationship with an increase in ADPN (r = −.71 and r = −.44, P < .007, respectively) and reduction in VF/SC fat (r = .41 and r = .37, P < .03 respectively).Conclusions: Reduction in VF and improved VF/SC‐distribution, combined with an increase in ADPN, mediate the histological benefits of PPAR‐γ action, highlighting the central role of fat metabolism and its distribution on steatohepatitis disease activity in patients with NASH.
- 9 September 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (9) , e234764
Adult hypophosphatasia manifests in a marathon runner
A 49-year-old woman, previously healthy, presented with recurrent fractures provoked by minimal trauma. She had sustained seven fractures over the previous 2 years. While she was an avid runner, her injuries were determined to be out of proportion to the degree of trauma. Initial evaluation, exploring the more common causes such as low bone density and abnormal vitamin D metabolism, was unremarkable. On repeat of the some of the tests, a low alkaline phosphatase (AP) was noted, which raised suspicion for hypophosphatasia (HPP), a rare cause of recurrent fractures. Subsequent workup revealed a low bone-specific AP and elevated vitamin B6. Subsequently, genetic testing confirmed the diagnosis of adult-onset HPP caused by a heterozygous mutation c.407G>A in the ALPL gene. Asfotase alfa was started; however, the patient developed an allergic reaction leading to the discontinuation of the drug.
- 9 September 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (9) , e234764
Adult hypophosphatasia manifests in a marathon runner
A 49-year-old woman, previously healthy, presented with recurrent fractures provoked by minimal trauma. She had sustained seven fractures over the previous 2 years. While she was an avid runner, her injuries were determined to be out of proportion to the degree of trauma. Initial evaluation, exploring the more common causes such as low bone density and abnormal vitamin D metabolism, was unremarkable. On repeat of the some of the tests, a low alkaline phosphatase (AP) was noted, which raised suspicion for hypophosphatasia (HPP), a rare cause of recurrent fractures. Subsequent workup revealed a low bone-specific AP and elevated vitamin B6. Subsequently, genetic testing confirmed the diagnosis of adult-onset HPP caused by a heterozygous mutation c.407G>A in the ALPL gene. Asfotase alfa was started; however, the patient developed an allergic reaction leading to the discontinuation of the drug.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1463-P: Relationship between Hepatic and Adipose Tissue Insulin Resistance with Liver Fibrosis in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
The ADA recommends screening for liver fibrosis in all patients with T2DM and with elevated ALT or steatosis. However, the factors that may predispose to hepatic fibrosis, such as comorbid conditions or insulin resistance (IR), have not been carefully examined. To this end, we studied patients with T2DM and NAFLD/fibrosis screened in an outpatient clinical setting. Screening for steatosis was done by controlled attenuation parameter (CAP), fibrosis by liver stiffness (LSM) with vibration-controlled transient elastography (VCTE). Out of 527 patients screened, 350 (66%) had steatosis (age: 60±12 years; BMI: 33±6 kg/m2; A1c: 7.5±1.7%). Based on VCTE, they were divided into LSM ≥ 7.0 kPa (moderate-to-severe fibrosis; n=69) or LSM ≤ 7.0 kPa (no or mild fibrosis; n=281). We measured hepatic (HOMA) and adipose tissue (Adipo-IR: fasting FFA x insulin) IR, FIB-4 and CK-18 (biomarkers of liver fibrosis). Results are summarized in the Table. Patients with fibrosis had more steatosis, worse HOMA/Adipo-IR and more severe metabolic syndrome. Presence of fibrosis was not evident in most patients by AST/ALT >40 U/L (elevated in just 26%) or FIB-4, but CK-18 was higher. In conclusion, clinicians should strongly suspect liver fibrosis in patients with T2DM that have the most unfavorable metabolic profile. Disclosure: S. Kalavalapalli: None. R. Lomonaco: None. E. Godinez: None. N. Fanous: None. L.J. Tejera: None. A. McCauley: None. L. Mansour: None. S. Shrestha: None. J.S. Marte: None. J. Fakhry: None. H. Wang: None. A. Vargas: None. D. Barb: None. F. Bril: None. K. Cusi: Consultant; Self; Allergan plc., AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc. Research Support; Self; Cirius Therapeutics, Echosens, Eli Lilly and Company, Inventiva Pharma, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Poxel SA, Zydus Pharmaceuticals, Inc. Funding: Echosens
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1463-P: Relationship between Hepatic and Adipose Tissue Insulin Resistance with Liver Fibrosis in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
The ADA recommends screening for liver fibrosis in all patients with T2DM and with elevated ALT or steatosis. However, the factors that may predispose to hepatic fibrosis, such as comorbid conditions or insulin resistance (IR), have not been carefully examined. To this end, we studied patients with T2DM and NAFLD/fibrosis screened in an outpatient clinical setting. Screening for steatosis was done by controlled attenuation parameter (CAP), fibrosis by liver stiffness (LSM) with vibration-controlled transient elastography (VCTE). Out of 527 patients screened, 350 (66%) had steatosis (age: 60±12 years; BMI: 33±6 kg/m2; A1c: 7.5±1.7%). Based on VCTE, they were divided into LSM ≥ 7.0 kPa (moderate-to-severe fibrosis; n=69) or LSM ≤ 7.0 kPa (no or mild fibrosis; n=281). We measured hepatic (HOMA) and adipose tissue (Adipo-IR: fasting FFA x insulin) IR, FIB-4 and CK-18 (biomarkers of liver fibrosis). Results are summarized in the Table. Patients with fibrosis had more steatosis, worse HOMA/Adipo-IR and more severe metabolic syndrome. Presence of fibrosis was not evident in most patients by AST/ALT >40 U/L (elevated in just 26%) or FIB-4, but CK-18 was higher. In conclusion, clinicians should strongly suspect liver fibrosis in patients with T2DM that have the most unfavorable metabolic profile. Disclosure: S. Kalavalapalli: None. R. Lomonaco: None. E. Godinez: None. N. Fanous: None. L.J. Tejera: None. A. McCauley: None. L. Mansour: None. S. Shrestha: None. J.S. Marte: None. J. Fakhry: None. H. Wang: None. A. Vargas: None. D. Barb: None. F. Bril: None. K. Cusi: Consultant; Self; Allergan plc., AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc. Research Support; Self; Cirius Therapeutics, Echosens, Eli Lilly and Company, Inventiva Pharma, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Poxel SA, Zydus Pharmaceuticals, Inc. Funding: Echosens